Related Experiment Video

Updated: May 20, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

Olaparib, PARP1 inhibitor in ovarian cancer

Claudia Marchetti1, Ludovica Imperiale, Maria Luisa Gasparri

  • 1Sapienza University of Rome, Department of Gynecologic-Obstetrical and Urologic Sciences, Viale del Policlinico, 155 - 00161, Rome, Italy. clamarchetti@libero.it

Expert Opinion on Investigational Drugs
|July 14, 2012
PubMed
Abstract

Insights

Olaparib, a PARP inhibitor, shows promise for treating ovarian cancer, including BRCA-mutated and sporadic types, offering a new targeted therapy approach. Further research is essential to validate these encouraging findings.

Area of Science:

  • Gynecologic Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Ovarian cancer is a leading cause of gynecologic cancer mortality with limited treatment outcomes for advanced or recurrent disease.
  • Targeted therapies offer a promising approach to improve tumor kill and reduce toxicity compared to conventional treatments.
  • Polyadenosine diphosphate-ribose polymerase (PARP) inhibitors are a key area of investigation in novel ovarian cancer therapies.

Purpose of the Study:

  • To analyze and discuss preclinical and clinical studies of Olaparib, a prominent PARP inhibitor, in the context of ovarian cancer treatment.
  • To review the current landscape of Olaparib research, including ongoing clinical trials and recent congress presentations.

Main Methods:

  • Systematic review of English peer-reviewed articles from Medline and Cochrane Database.
  • Inclusion of ongoing Phase I and II clinical trials registered with the National Cancer Institute.
  • Consideration of abstracts from major international congresses related to Olaparib.

Main Results:

  • Olaparib is the most investigated PARP inhibitor for ovarian cancer.
  • The drug targets molecular-specific pathways, showing potential in both BRCA1/BRCA2-mutated and sporadic ovarian cancers.
  • Initial results suggest Olaparib is a promising therapeutic option.

Conclusions:

  • Ovarian cancer is often characterized by poor prognosis and drug resistance.
  • Targeted therapies, such as PARP inhibition with Olaparib, represent a significant advancement.
  • Further investigation is required to confirm the efficacy and long-term benefits of Olaparib in ovarian cancer treatment.

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...